ABSTRACT
Differences between phenazepam formulations were found in the clinical study of drug effects on the psychophysiological state in patients with anxiety disorder. Phenazepam did not cause negative changes of psychophysiological parameters. In patients with anxiety disorders, the most significant positive therapeutic actionon psychophysiological state was observed in the case of using transdermal phenazepam formulation.
Subject(s)
Anxiety Disorders/drug therapy , Anxiety Disorders/psychology , Attention/drug effects , Benzodiazepines , Administration, Cutaneous , Adolescent , Adult , Anxiety Disorders/physiopathology , Attention/physiology , Benzodiazepines/therapeutic use , Dosage Forms , Female , Humans , Male , Middle Aged , Motor Activity/drug effects , Reaction Time/drug effects , Task Performance and AnalysisABSTRACT
Self-evaluation of the effect of single-dose (15 mg) ladasten administration versus placebo has been studied in patients with neurasthenia diagnosis. Relationships between self-evaluation parameters and personal features, psychopathological and psychophysiological parameters of patients, drug action characteristics, and course treatment effectiveness have been analyzed. Results suggest that the self-rated high tolerability of ladasten treatment is comparable with that of placebo. No relationships are found between the self-evaluated single-dose effects of ladasten and personal features of patients. Correlations of the self-estimations and some psychopathological and psychophysiological parameters before treatment, main drug effects, and overall course treatment effectiveness are revealed, whereas the self-evaluation of placebo effect was related to personal features.
Subject(s)
Adamantane/analogs & derivatives , Affect/drug effects , Anti-Anxiety Agents/therapeutic use , Motor Activity/drug effects , Neurasthenia/drug therapy , Adamantane/administration & dosage , Adamantane/therapeutic use , Administration, Oral , Adult , Anti-Anxiety Agents/administration & dosage , Diagnostic Self Evaluation , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Neurasthenia/diagnosis , Neurasthenia/physiopathology , Physical Examination , Placebo Effect , Psychophysiology , Research Design , Sleep Initiation and Maintenance Disorders , Sleep Stages , Treatment OutcomeABSTRACT
An aim of a randomized blind study was to assess therapeutic efficacy and safety of ladasten used as an antiastenic drug in patients with neurasthenia. Tasks of the study included the investigation of characteristics of therapeutical actions, efficacy of the drug comparing to placebo, possible side-effects and probability of the development of "withdrawal syndromes". The design of the study included a wash-out period, a monotherapy with ladasten and placebo during 28 days and a final 1-week period of receiving placebo. Standartisized objective and subjective methods of mental state evaluation in patients were administered. The results obtained suggest that a combination of psychostimulant and anxiolytic actions in the spectrum of psychotropic activity of ladasten determines the its high therapeutic efficacy in asthenic disorders. It has been found that ladasten is superior in the rate and degree of reduction of main symptoms of asthenic syndrome compared to placebo. The absence of "withdrawal syndrome" after the drug withdrawal reveals the lack of addictive potential in this drug.
Subject(s)
Adamantane/analogs & derivatives , Anti-Anxiety Agents/therapeutic use , Central Nervous System Stimulants/therapeutic use , Neurasthenia/drug therapy , Adamantane/administration & dosage , Adamantane/therapeutic use , Anti-Anxiety Agents/administration & dosage , Central Nervous System Stimulants/administration & dosage , Humans , Neurasthenia/diagnosis , Placebos , Time Factors , Treatment OutcomeABSTRACT
A standardized clinical and pharmacological trial of the peculiarities of action and efficacy of aphobazol, a new anxyolytic with non-benzodiazepine structure, has been conducted. An effect of the drug on different anxiety disorders has been studied. It is shown that combined anxyolytic and activating action exerted the main effect. The best efficacy of aphobazol was found in anxiety disorders of "simple" structure. In more complicated anxiety disorders, aphobazol efficacy depended on the correlation between clinical appearances of deeper registers and anxiety affect. The best results have been achieved in patients with acute anxiety-phobic disorders, in the structure of which sensible anxiety with episodes of generalization, dominating vivid ideas, sensibly saturated phobias with pronounced autonomic disorders and senestalgias prevailed. In case of chronic disease course, with formation of more inert, "complex" in structure and deep by register psychopathological disorders (cognitive character of anxiety, appearances of agoraphobia and avoidance behavior, heteronomous body sensations and hypochondriac activity), the efficacy of aphobazol treatment was significantly lower. In this case a therapy combined with selective inhibitors of serotonin reuptake and neuroleptics is needed.
